11. Subjects with chronic infection by HCV who are treated or untreated are allowed on study. Subjects with a past or resolved HBV infection, defined as having a negative HBsAg test and a positive total hepatitis B core antibody (HBcAb) test and negative HBV DNA test at screening, are eligible for the study. In addition, subjects with successful treatment (defined as sustained virologic response [SVR12] or SVR24) are allowed as long as 4 weeks have passed between completion of HCV therapy and start of study drug.